LSE:GSK.L News 28 November 2025 - 7 February 2026

GSK shares closed Friday up 0.83% at a 52-week high after the EU approved Nucala for certain uncontrolled COPD patients. Insider filings showed chairman Jonathan Symonds bought 2,500 shares while executive David Redfern sold 100,000. The FTSE 100 rose 0.6%. Broker ratings on GSK remained mixed.

London, Jan 8, 2026, 09:12 GMT — Regular session GSK (GSK.L) shares slipped on Thursday as investors weighed upbeat headlines on its experimental hepatitis B therapy against a lack of hard cure-rate data. The stock was down 0.9% at 1,883.5 pence in London trade, after moving between 1,880 and 1,896.5 pence and staying near the top of its 52-week range. Investing.com+1 GSK said two Phase III trials of bepirovirsen met their primary endpoint — the main goal set before the studies began — and delivered a statistically significant “functional cure” rate on top of standard treatment. A functional cure, as

GSK plc (LON:GSK; NYSE:GSK) is drifting quietly higher on Friday, 28 November 2025, with investors digesting a fresh “Hold” consensus from Wall Street, another round of share buybacks and a still‑busy drug pipeline that has pushed the stock close to 12‑month highs. In London, GSK’s shares are trading around 1,806p, up roughly 0.2% on the day, within a narrow intraday range of 1,802.5p–1,810p and not far from their 52‑week high of 1,830p.Investing.com+1 On the New York Stock Exchange, the company’s American Depositary Receipts (ADRs) change hands at about $48.02, virtually flat in early trading but hovering just below a 12‑month